Page last updated: 2024-11-13

1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1-Palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzePC)

**1-Palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PAzePC)** is a synthetic phospholipid. It's essentially a modified version of a naturally occurring phospholipid, phosphatidylcholine (PC).

**Structure:**

* **Palmitoyl (C16:0):** A saturated fatty acid chain with 16 carbon atoms.
* **Azelaoyl (C9:0):** A saturated fatty acid chain with 9 carbon atoms.
* **sn-Glycero-3-phosphocholine:** The backbone of the phospholipid, including the glycerol molecule and the choline head group.

**Importance in Research:**

PAzePC is particularly important for research in several areas:

1. **Lipid Metabolism & Signaling:**
* PAzePC is a valuable tool for studying lipid metabolism and signaling pathways. By incorporating it into model systems, researchers can analyze how different lipids interact with cellular processes.
* It can be used to investigate the role of specific lipids in various cellular functions, such as membrane fluidity, cell signaling, and enzyme activity.

2. **Membrane Structure & Function:**
* PAzePC can be incorporated into artificial membranes, like liposomes. This allows researchers to study how different lipids affect membrane properties and function.
* By varying the fatty acid composition of PAzePC, researchers can explore the relationship between lipid structure and membrane properties like permeability, fluidity, and stability.

3. **Drug Delivery & Nanomedicine:**
* PAzePC is used to design and develop new drug delivery systems. Its unique properties make it suitable for encapsulating various drugs and delivering them to specific targets within the body.
* Researchers are investigating the use of PAzePC-based liposomes to improve the efficiency and safety of drug delivery.

4. **Biomaterials and Tissue Engineering:**
* PAzePC is being explored for its potential in creating biocompatible materials for tissue engineering applications. Its biodegradability and biocompatibility make it suitable for constructing scaffolds for tissue regeneration.
* It can be used to mimic the natural environment of cells, fostering their growth and differentiation.

**In summary:**

PAzePC is a versatile synthetic phospholipid with several applications in research, including lipid metabolism, membrane studies, drug delivery, and biomaterials. Its ability to mimic natural lipids while offering specific structural modifications makes it a valuable tool for understanding complex biological processes and developing new therapeutic strategies.

1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine : A 1,2-diacyl-sn-glycero-3-phosphocholine having palmitoyl and azelaoyl groups at positions 1 and 2 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID46907870
CHEBI ID61817
SCHEMBL ID22607965
MeSH IDM0520995

Synonyms (28)

Synonym
pc(16:0/9:0(cooh))
1-hexadecanoyl-2-(9-carboxy-nonanoyl)-sn-glycero-3-phosphocholine
LMGP20010007
1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine
2-o-azelaoyl-1-o-palmitoyl-sn-glycero-3-phosphocholine
16:0-09:0(aldo)pc
CHEBI:61817 ,
1-o-palmitoyl-2-o-azelaoyl-sn-glycero-3-phosphocholine
(2r)-2-[(8-carboxyoctanoyl)oxy]-3-(palmitoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
16:0-09:0(aldo)phosphocholine
EPITOPE ID:153523
gtpl5427
azelaoyl pc
paz-pc
(2-{[(2r)-2-[(8-carboxyoctanoyl)oxy]-3-(hexadecanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium
1-palmitoyl-2-azelaoyl pc
GHQQYDSARXURNG-SSEXGKCCSA-N
1-o-hexadecanoyl-2-o-(9-carboxyoctanoyl)-sn-glyceryl-3-phosphocholine
HMS3649G17
J-003538
pazepc, 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine, chloroform
pazepc, 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine, powder
2-[(8-carboxyoctanoyl)oxy]-3-(hexadecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
DTXSID20922533
Q27088247
[(2r)-2-(8-carboxyoctanoyloxy)-3-hexadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
SCHEMBL22607965
AKOS040754953
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,2-diacyl-sn-glycero-3-phosphocholineThe conjugate base of a 1,2-diacyl-sn-glycero-3-phosphocholine compound formed by deprotonation of the phosphate OH group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (18.75)29.6817
2010's13 (81.25)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.09

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.09 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.09)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]